Troponin I Levels Correlate with Cardiac MR LGE and Native T1 Values in Duchenne Muscular Dystrophy Cardiomyopathy and Identify Early Disease Progression

Voleti, Sonia; Olivieri, Laura; Hamann, Karin; Gordish‐Dressman, Heather; Spurney, Christopher F.

doi:10.1007/s00246-020-02372-5

Cited by 18 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We hypothesize that serum cTnI levels may increase with the progression of MF because the observed timings of brosis and cTnI rise are the same (early second decade of life). Recently, Sonia et al reported that cTnI values correlated with cMRI ndings in patients with DMD cardiomyopathy [44]. They showed that cTnI levels in DMD patients with mild LGE were signi cantly increased compared to those in patients without LGE.…”

Section: Discussionmentioning

confidence: 97%

Comparison of the Levels of Cardiac Troponin I in Patients with Duchenne and Becker Muscular Dystrophies to Assess Cardiac Dysfunction

Yamaguchi

Awano

Yamamoto

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Cardiac troponin I (cTnI), uniquely expressed in the myocardium, is a marker for acute myocardial injury. Its clinical significance in Duchenne and Becker muscular dystrophy (DMD and BMD) and its relation to alpha-actinin-3 (ACTN3) genotype as a genetic modifier of cardiomyopathy are still unknown.Methods and Results: Overall, 529 and 131 serum cTnI values of 127 DMD and 47 BMD patients, respectively, were reviewed. cTnI elevation was generally observed in the second decade of life. Both cTnI levels and the proportion of abnormal cTnI levels were significantly higher in DMD patients than in BMD patients (age range: 1< years ≤10 and 10< years ≤18 and 10< years ≤18, respectively). Decreased left ventricular ejection fraction was observed after cTnI elevation in both populations. cTnI levels by age in DMD patients with ACTN3 null genotype tended to increase highly and early.Conclusions: Myocardial injury indicated by cTnI was more common and severe in DMD patients than in BMD patients. cTnI elevation preceding cardiac dysfunction may represent an early phase of cardiomyopathy progression and may be a biomarker for early detection of cardiomyopathy in DMD and BMD patients. The ACTN3 null genotype may be a risk factor for early myocardial injury.

show abstract

Section: Discussionmentioning

confidence: 97%

Comparison of the Levels of Cardiac Troponin I in Patients with Duchenne and Becker Muscular Dystrophies to Assess Cardiac Dysfunction

Yamaguchi

Awano

Yamamoto

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…In particular, serum levels of cardiac troponin I and T are known to be associated to the extension of myocardial damage, but there are conflicting results about their diagnostic and prognostic implications in the DMD DCM [ 18 , 19 , 20 ]. Recently, Voleti et al [ 21 ] demonstrated that troponin I levels were significantly elevated in subjects with mild late gadolinium enhancement (LGE) compared to those without LGE. Interestingly, there was a lack of positive association between troponin levels and moderate-to-severe LGE probably because of a decreased enzyme leak at later stages of the disease, when most of myocardium has already been substituted by fibrofatty tissue.…”

Section: Cardiovascular Biomarkersmentioning

confidence: 99%

“…Interestingly, there was a lack of positive association between troponin levels and moderate-to-severe LGE probably because of a decreased enzyme leak at later stages of the disease, when most of myocardium has already been substituted by fibrofatty tissue. Hence, Troponin I could provide useful information to monitor patients in the clinical practice and further studies are required [ 21 ].…”

Section: Cardiovascular Biomarkersmentioning

confidence: 99%

Duchenne Dilated Cardiomyopathy: Cardiac Management from Prevention to Advanced Cardiovascular Therapies

Adorisio

Mencarelli

Cantarutti

et al. 2020

JCM

View full text Add to dashboard Cite

Duchenne muscular dystrophy (DMD) cardiomyopathy (DCM) is characterized by a hypokinetic, dilated phenotype progressively increasing with age. Regular cardiac care is crucial in DMD care. Early recognition and prophylactic use of angiotensin converting enzyme inhibitors (ACEi) are the main stay therapeutic strategy to delay incidence of DMD-DCM. Pharmacological treatment to improve symptoms and left ventricle (LV) systolic function, have been widely implemented in the past years. Because of lack of DMD specific drugs, actual indications for established DCM include current treatment for heart failure (HF). This review focuses on current HF strategies to identify, characterize, and treat DMD-DCM.

show abstract

“…In particular, the guidelines for enhanced validation of antibodies designed by the International Working Group for Antibody Validation (IWGAV), an ad-hoc formed group of leading researchers, promotes rigorous validation of such reagents and has been adopted by researchers and leading antibody producers [89][90][91]. Beside antibodies development of short single-stranded oligonucleotides as affinity reagents and the SomaLogic technology enabled researchers to analyze more than 1,000 targets in cross-sectional studies in the context of DMD [92][93][94][95][96]. The assay relies on the capture of the target in its native conformation to immobilized protein-specific Slow Off-rate Modified DNA aptamers (SOMAmers).…”

Section: Proteomic Technologies and Biomarker Discovery And Validationmentioning

confidence: 99%

Duchenne Muscular Dystrophy: recent advances in protein biomarkers and the clinical application

Szigyarto

2020

Expert Review of Proteomics

View full text Add to dashboard Cite

Introduction: Early biomarker discovery studies have praised the value of their emerging results, predicting an unprecedented impact on health care. Biomarkers are expected to provide tests with increased specificity and sensitivity compared to existing measures, improve the decision-making process, and accelerate the development of therapies. For rare disorders, like Duchenne Muscular Dystrophy (DMD) such biomarkers can assist the development of therapies, therefore also helping to find a cure for the disease. Area covered: State-of-the-art technologies have been used to identify blood biomarkers for DMD and efforts have been coordinated to develop and promote translation of biomarkers for clinical practice. Biomarker translation to clinical practice is however, adjoined by challenges related to the complexity of the disease, involving numerous biological processes, and the limited sample resources. This review highlights the current progress on the development of biomarkers, describing the proteomics technologies used, the most promising findings and the challenges encountered. Expert opinion: Strategies for effective use of samples combined with orthogonal proteomics methods for protein quantification are essential for translating biomarkers to the patient's bed side. Progress is achieved only if strong evidence is provided that the biomarker constitutes a reliable indicator of the patient's health status for a specific context of use.

show abstract

Troponin I Levels Correlate with Cardiac MR LGE and Native T1 Values in Duchenne Muscular Dystrophy Cardiomyopathy and Identify Early Disease Progression

Cited by 18 publications

References 18 publications

Comparison of the Levels of Cardiac Troponin I in Patients with Duchenne and Becker Muscular Dystrophies to Assess Cardiac Dysfunction

Comparison of the Levels of Cardiac Troponin I in Patients with Duchenne and Becker Muscular Dystrophies to Assess Cardiac Dysfunction

Duchenne Dilated Cardiomyopathy: Cardiac Management from Prevention to Advanced Cardiovascular Therapies

Duchenne Muscular Dystrophy: recent advances in protein biomarkers and the clinical application

Contact Info

Product

Resources

About